E. Taylor

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Maria A. Rodriguez, P. Mclaughlin, S. Neelapu, 2020, Leukemia & lymphoma.